Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Cravit Ranked No. 1 on Both HP and GP Markets: Rep Track Survey
August 31, 2009
- Full-Scale Flu Epidemic May Have Begun: Health Minister
August 31, 2009
- Makers' FY2009 1st Qtr Business Roundup -2-
August 31, 2009
- GSK Starts Adjusting Shipments of Relenza due to Rush of Orders
August 31, 2009
- Makers' FY2009 1st Qtr Business Roundup -1-
August 31, 2009
- Sales of Ethical Drugs Up 7.9% in June: Crecon
August 31, 2009
- Kowa Licenses Livalo to MTPC in Taiwan, Indonesia
August 31, 2009
- SELF-MEDICATION NEWS IN BRIEF
August 31, 2009
- DSP to Transform Itself into Global Research-Driven Pharma: President Tada
August 31, 2009
- Wholesalers Should Increase Profits by Offering Value through MSs: Mr Bessho
August 24, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 24, 2009
- Wholesalers' Gross Profit Rate Down to 7.09%
August 24, 2009
- Drug Costs Down 1.6% in Municipal Hospitals in FY2008
August 24, 2009
- Top-Four Wholesalers' FY2009 1st Qtr Business Roundup
August 24, 2009
- GE Healthcare, Terumo Agree on Joint Marketing
August 24, 2009
- Makers' FY2009 1st Qtr Business Roundup
August 24, 2009
- GE Healthcare Integrates Two Subsidiaries to Create GE Healthcare Japan
August 24, 2009
- AZ, Astellas to Copromote Symbicort in Japan
August 24, 2009
- SELF-MEDICATION NEWS IN BRIEF
August 24, 2009
- Daiichi Sankyo, Eli Lilly Launch Effient in the US
August 24, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…